Dossier assessment
Selinexor (multiple myeloma, fifth line) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Selinexor (multiple myeloma, fifth line) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Selinexor (multiple myeloma, fifth line) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
adult patients with multiple myeloma who have received at least four previous treatments and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy
added benefit not proven
Project details
- Project no.
- A22-101
- Commission
- Commission awarded on 29.09.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed